Karius, headquartered in US, remains privately held in the healthcare / diagnostics space. The stock is not listed on any public market.
Karius has no published valuation.
Khosla VenturesLEADSSoftBank Vision Fund 2LEAD
DCVCLEAD
Lightspeed Venture PartnersLEAD
General Catalyst55AM VenturesGGilde HealthcareHHBM Healthcare InvestmentsBBlue Water Life SciencesKhosla VenturesSoftBank Vision Fund 2DCVCLightspeed Venture PartnersKarius provides unique genomic insights by detecting microbial cell-free DNA circulating throughout the body from pathogens that may cause infections. It is delivering a commercially available liquid biopsy for infectious diseases that can diagnose deep-seated and bloodstream infections rapidly and non-invasively, helping healthcare providers detect infections faster for immunocompromised patient care.
Karius describes itself as a clinical metagenomics company focused on elevating the treatment of infectious disease, and separately as a venture-backed life science startup focused on transforming the way infectious diseases are diagnosed, combining next-generation sequencing with genomic analysis.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Karius.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Karius availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Karius included.
The closest healthcare / diagnostics peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Karius is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
